GEN-MKT-18-7897-A
Feb 29, 2016 | Biopharma, Blogs | 0 comments
Traditionally, the pharmacokinetic profile of biotherapeutics such as insulin glargine, adalimumab, trastuzumab and others, used gold standard LBAs to assess dose-response during drug discovery and development. However, LBAs require a specific antibody reagent to be developed for each mAb variant, a process that is often incompatible with the compressed timeframes encountered during the initial stages of drug development. More recently, LC-MS/MS-based methods have come to the forefront as a feasible approach for the quantification of biotherapeutics in biological matrices, with many of these methods relying on proteolytic digestion of the target mAb and quantification of multiple unique signature peptides, which are equivalent to levels of the whole protein. But, to drive the real biological need, we have to quantify the pharmacologically active or free form of the drug to assess safety, efficacy and proper dosing regimen. Here we present a solution to get the best of both technologies: an LBA strategy to capture the active form of the drug; and an LC-MS assay to selectively quantify the free and circulating drug.
With the launch of the ZenoTOF 8600 system, EAD has taken a significant leap forward in becoming a routine tool for metabolomics and lipidomics workflows. Building on the foundation laid by the ZenoTOF 7600 system, the 8600 system introduces enhanced sensitivity, function speed improvements, and multimodal capabilities that make EAD more practical and scalable for daily use. This blog explores how these advancements are transforming EAD from a specialized technique into a robust and accessible solution for high-throughput structural analysis, enabling researchers to unlock deeper insights with greater efficiency.
In your lab, time is not just a resource. It’s a necessity and every moment counts. Yet, unplanned downtime can disrupt this delicate balance. Even a brief interruption can set your team back in multiple ways.
In a recent webinar, which is now available on-demand, Holly Lee powerful strategies to tackle complex residue testing. From boosting throughput to fine-tuning method sensitivity, Holly shared key ways to maximize performance across large pesticide panels.
Posted by
You must be logged in to post a comment.
Share this post with your network